Announcement PDF Market Announcement 21 September 2026 21 September 2026 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au #11142542v1 Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt Trading in the securities of Paradigm Biopharmaceuticals Limited (‘PAR’) will be halted at the request of PAR, pending the release of an announcement by PAR. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 23 September 2026; or • the release of the announcement to the market. PAR’s request for a trading halt is attached below for the information of the market. Issued by ASX Compliance AUSTRALIA (Head Office) Paradigm Biopharmaceuticals Limited Level 15, 500 Collins St Melbourne, Victoria 3000 USA Paradigm Biopharmaceuticals (USA) Inc 31 West 34th St, 8th Floor New York, New York 10001 IRELAND Paradigm Biopharmaceuticals (Ireland) Limited Fitzwilliam Hall, Fitzwilliam Place Dublin 2 paradigmbiopharma.com | investorrelations@paradigmbiopharma.com 21 September 2026 By email: melissa.kostopoulos@asx.com.au Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) ASX Limited Dear Melissa Request for a trading halt Paradigm Biopharmaceuticals Limited (ACN 169 346 963) (the Company), requests that the Company's quoted securities (ASX Codes: PAR and PAROB) be placed into a trading halt with immediate effect from the open of trading today, Monday, 21 September 2026. For the purposes of Listing Rule 17.1, the Company provides the following information: 1. the Company is seeking the trading halt pending the release of an announcement by the Company to the market in relation to the Interim Analysis results for its Phase 3 Clinical Trial (IA Results); 2. the Company requests that the trading halt continues until the earlier of an announcement regarding the IA Results being released to the market or the commencement of trading on Wednesday 23 September 2026; and 3. the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt. Please contact us should you have any questions. Yours sincerely Abby Macnish Niven Company Secretary For and on behalf of the Board of Paradigm Biopharmaceuticals Limited Paradigm Biopharmaceuticals Ltd ABN: 94 169 346 963